NJHA Charts Rise and Fall of COVID Hospitalizations; Peak Occurred April 14

NJHA: A new bulletin from the New Jersey Hospital Association reviews the “rise and fall” of COVID-19 in New Jersey hospitals, charting the peak day of hospital activity on April 14 and the steady decline that is bringing the state’s hospitals close to pre-COVID capacity levels.

New Jersey reported its first COVID-19 case on March 4. The rapid rise of the virus in New Jersey culminated on April 14, when the state’s hospitals experienced the following peaks:

  • 8,084 patients were hospitalized with COVID-19
  • 82 percent of intensive care beds were filled
  • 62 percent of ventilators were in use.

These numbers represent a statewide average. However, COVID-19 activity varied significantly across regions of the state, with some facilities in northern New Jersey near 100 percent of capacity in mid-April.

The bulletin includes data through May 20, when 3,208 patients were hospitalized with COVID-19. That’s a 60 percent decline from hospitals’ peak.

“One of the greatest fears – that COVID cases would exceed our available beds and ventilators – never materialized, thanks to hospitals’ nimbleness in expanding capacity in our healthcare system,” said NJHA President and CEO Cathy Bennett. “It’s heartening to see the decline of COVID patients in our hospitals. We remain ever vigilant to not only protect New Jerseyans today, but also to build up our ability to respond to any signs of renewed virus activity.”

Other data in the review from NJHA’s Center for Health Analytics, Research and Transformation, captured through May 20, shows:

  • 150,339 N.J. residents have tested positive for the virus, which represents 1.7 percent of the state’s population. Nationally, more than 1.5 million have been infected, which represents approximately 0.45 percent of the population.
  • 10,747 N.J. residents have died from COVID-19, representing 7.1 percent of the state’s total COVID cases. Across the country, more than 90,000 individuals have died, for a national death rate at just over 6 percent.

Go to www.njha.com/CHART to view the full CHART bulletin.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”